https://doi.org/10.55788/1f900ab1
Prof. G.R. Scott Budinger (Northwestern University, IL, USA) presented current data concerning COVID-19 patients at imminent risk of dying due to ARDS who had received lung transplantations [1ā4]. He started by saying that āpatients with COVID-19-associated ARDS who received lung transplants had similar outcomes compared with transplant patients without COVID-19, despite modestly increased early post-op complications.ā
In the retrospective study, Prof. Budinger mostly focused on the case series including 102 patients who underwent a lung transplant at Northwestern Memorial Hospital between January 2020 and September 2021, including 30 patients who had COVID-19-associated ARDS [3]. While rates of transplant complications and length of stays in intensive care units were both higher in the group with COVID-19, patient survival in both groups was not significantly different. Overall, this data was very similar to that of the other studies [2,4].
Prof. Budinger pointed out that this finding is encouraging for the treatment of patients with COVID-19 who have no other options. Furthermore, the collective data can reassure the community that precious resources such as donor lungs will not necessarily have poorer outcomes in candidates with COVID-19.
- Budinger GS, et al.Lung Transplantation for COVID-19-Associated ARDS. Session A2, ATS International Conference 2022, San Francisco, CA, USA, 13ā18 May.
- Bharat A, et al. Lancet Respir Med. 2021;9(5):487ā497.
- Kurihara C, et al. JAMA. 2022;327(7):652ā661.
- Roach A, et al. N Engl J Med 2022;386(12):1187ā1188.
Copyright Ā©2022 Medicom Medical Publishers
Posted on
Previous Article
« COVI-PRONE trial on its back Next Article
Nebulised aviptadil āfutileā in I-SPY COVID-19 trial »
« COVI-PRONE trial on its back Next Article
Nebulised aviptadil āfutileā in I-SPY COVID-19 trial »
Table of Contents: ATS 2022
Featured articles
Letter from the Editor
COVID-19
Nebulised aviptadil āfutileā in I-SPY COVID-19 trial
Lung transplantation after COVID-19-associated ARDS
Mesenchymal stem cells offer no benefit in COVID-19
Alpha-1 antitrypsin for ARDS secondary to severe COVID-19
Frailty prevalent 5 months following hospitalisation for COVID-19
Paediatric long COVID lacks definitions
Asthma Clinical Trial Updates
MANDALA and DENALI pattern success for albuterol-budesonide in asthma
ACOUSTICS data sounds good for adolescent asthma exacerbations
Type 2 asthma in children managed by dupilumab, despite atopic comorbidities
NAVIGATOR steers asthma patients to tezepelumab
High-intensity interval training slashes daily corticosteroids in asthma
Chronic Obstructive Pulmonary Disease
Threeās a crowd for triple therapy in COPD
Higher 1-year COPD mortality after hospitalisation for White patients
Reducing dyspnoea in chronic lung disease through weight loss
CT-evident mucus plugs in COPD associated with death
Home-based rehabilitation improves COPD: a randomised study
Highlighted Advances
Novel P2X3 antagonist can SOOTHE chronic cough
Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis
Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?
PAGANINI phase 2b data promising for eliapixant
POISE-3: Tranexamic acid for non-cardiac surgery
Obstructive sleep apnoea in most children with pulmonary hypertension
No screening evidence for COPD
Novel PDE4B inhibitor offers breakthrough for IPF
Hydrocortisone does not help preterm infants
CPAP temporarily supports pulmonary oxygenation in morbidly obese patients
ISAACC trial: CPAP controls blood pressure in ACS patients with severe OSA
Related Articles
October 30, 2022
Impact of CPAP on cardiac endpoints in OSA
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com